查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1243905

腦膜炎疫苗的全球市場

Meningococcal Vaccines
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

腦膜炎疫苗的全球市場2030年前將達到49億美元

在COVID-19後改變的商務環境中，2022年33億美元的腦膜炎疫苗的全球市場，在2022年～2030年預計將以4.9％的年複合成長率增長，到2030年前將達到49億美元。本報告所分析之市場區隔之一的4價疫苗年複合成長率將記錄5.2％，到分析期間結束時將達到28億美元。考慮疫情後的復甦，2價的市場領域今後8年的年複合成長率將修正為4.6％。

美國市場估算為9億9,500萬美元，中國則將以年複合成長率4.5％增長

美國的腦膜炎疫苗市場在2022年估算為9億9,500萬美元。作為世界第2大經濟大國的中國，在2022年～2030年預計將以年複合成長率4.5％推移，2030年前將達到8億4,970萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以4.6％和3.8％的速度成長。在歐洲市場中，德國以年複合成長率約4％成長。

調查對像企業範例

  • Baxter International, Inc.
  • Bio-Med Pvt., Ltd.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP13255

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Meningococcal Vaccines Market to Reach $4.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Meningococcal Vaccines estimated at US$3.3 Billion in the year 2022, is projected to reach a revised size of US$4.9 Billion by 2030, growing at aCAGR of 4.9% over the period 2022-2030. Quadrivalent, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$2.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bivalent segment is readjusted to a revised 4.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $995 Million, While China is Forecast to Grow at 4.5% CAGR

The Meningococcal Vaccines market in the U.S. is estimated at US$995 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$849.7 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Select Competitors (Total 42 Featured) -

  • Baxter International, Inc.
  • Bio-Med Pvt., Ltd.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Meningococcal Vaccines - Global Key Competitors Percentage Market Share in 2020 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Meningococcal Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Quadrivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World 8-Year Perspective for Quadrivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Bivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for Bivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Serotype A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for Serotype A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Serotype B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Serotype B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Serotype C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for Serotype C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Serotype W-135 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for Serotype W-135 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Serotypes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 19: World 8-Year Perspective for Other Serotypes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infants (Up to 2 years) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World 8-Year Perspective for Infants (Up to 2 years) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Children (Above 2 years) & Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World 8-Year Perspective for Children (Above 2 years) & Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 25: USA 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Canada 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Canada 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • JAPAN
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Japan 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Japan 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • CHINA
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 43: China 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 47: China 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • EUROPE
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 49: Europe 8-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Europe 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Europe 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • FRANCE
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 59: France 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 61: France 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • GERMANY
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Germany 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Germany 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Italy 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Italy 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • UNITED KINGDOM
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 77: UK 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 79: UK 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World 8-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2023 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 95: Rest of World 8-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2023 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 97: Rest of World 8-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2023 & 2030

IV. COMPETITION